Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial

被引：0
|
作者：
C. Belliveau
M. Barkati
G. Delouya
D. Taussky
M. C. Beauchemin
C. Lambert
L. Beaulieu
D. Beliveau-Nadeau
B. Nicolas
J. F. Carrier
E. Vigneault
C. Ménard
机构：
[1] CHUM - Centre Hospitalier de l’Université de Montréal,Radiation Oncology
[2] Université Laval,Radiation Oncology, Centre universitaire de Québec
来源：
Radiation Oncology | / 17卷
关键词：
Prostate cancer; Stereotactic radiotherapy; Focal brachytherapy; Quality of life; Magnetic resonance imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
    Belliveau, C.
    Barkati, M.
    Delouya, G.
    Taussky, D.
    Beauchemin, M. C.
    Lambert, C.
    Beaulieu, L.
    Beliveau-Nadeau, D.
    Nicolas, B.
    Carrier, J. F.
    Vigneault, E.
    Menard, C.
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [2] HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Toxicity of a Randomized Phase II Trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T.
    Hillmann, E. de Castro
    Berbiche, D.
    Truchon, D.
    Heliou, R.
    Mondat, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S90 - S91
  • [3] MR-Guided HDR Brachytherapy Boost in Localized Prostate Cancer Results of a Phase II Trial
    Johnny, C.
    Berlin, A.
    Weersink, R. A.
    Raman, S.
    Glicksman, R.
    Catton, C.
    Rink, A.
    Warde, P. R.
    Lao, B.
    Menard, C.
    Chung, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E397 - E397
  • [4] HDR BRACHYTHERAPY OF PROSTATE CANCER AS A BOOST AFTER EXTERNAL BEAM RADIOTHERAPY
    Kanikowski, M.
    Skowronek, J.
    Kubaszewska, M.
    Chichel, A.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S324 - S324
  • [5] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [6] Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
    Vigneault, E.
    Morton, G.
    Perulekar, W.
    Niazi, T.
    Springer, G.
    Barkati, M.
    Chung, P.
    Koll, W.
    Kamran, A.
    Montreal, M.
    Ding, K.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S975 - S976
  • [7] Stereotactic Body Radiotherapy (SBRT) Boost to Mimic High-Dose Rate (HDR) Brachytherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Study
    Al-Hanaqta, M.
    Loblaw, D. A.
    Chu, W.
    Ravi, A.
    Chiang, A. S., Jr.
    Jain, S.
    Chung, H. T.
    Vesprini, D.
    Morton, G.
    Deabreu, A.
    Mamedov, A.
    Zhang, L.
    Erler, D.
    Cheung, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S208 - S208
  • [8] EXTERNAL BEAM RADIOTHERAPY WITH HDR BRACHYTHERAPY BOOST AND ANDROGEN DEPRIVATION FOR PROSTATE CANCER
    Miller, S.
    Bucci, J.
    Chin, Y.
    Malouf, D.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S24 - S24
  • [9] A prospective randomised trial of HDR brachytherapy boost in radical radiotherapy for localised carcinoma of the prostate
    Hoskin, P.
    Ostler, P.
    Bownes, P.
    Woodruffe, M.
    Philips, H.
    Motohashi, K.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S148 - S148
  • [10] 5-year results of HDR brachytherapy, plus radiotherapy and ADT for intermediate prostate cancer: a phase II trial
    Jolicoeur, M.
    Tetreault-Laflamme, A.
    Nguyen-Huynh, T. V.
    Benoit, N.
    Guay, J. P.
    Fortin, B.
    Vincent, F.
    Lambert, C.
    Saad, F.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S562 - S563
12345